Abstract： Objective： Using non-targeted metabolomics techniques to analyze the potential biomarkers of different subtypes of damp-heat accumulation syndrome （equal severity of dampness and heat，heavier dampness，and heavier heat） in chronic hepatitis B （CHB），and provide an objective basis for fine syndrome differentiation in Chinese medicine from the perspective of small molecule metabolites. Methods： With strict inclusion and exclusion criteria， 58 patients with CHB （21 with equal severity of dampness and heat，16 with heavier dampness，and 21 with heavier heat） and 10 healthy volunteers were included. Fasting blood samples were collected in the morning，and differential metabolites between each group and healthy volunteers were compared using LC-MS metabolomics technology. Results： After screening， there were a total of 19 differential metabolites between patients with CHB and healthy volunteers. Among them，eight were differential metabolites of the group of CHB with damp-heat accumulation syndrome with equal severity of dampness and heat， three were in the group of the heavier dampness， three were in the group of heavier heat，and four were common differential metabolites of CHB with damp-heat accumulation syndrome. These differential metabolites involved 19 metabolic pathways， such as galactose metabolism， arachidonic acid metabolism， and glutathione metabolism. Through ROC analysis， arachidonic acid （AUC=0.80）， stearidonic acid （AUC=0.81）， methyl jasmonate （AUC=0.84）， and L-alanine （AUC=0.76） may be diagnostic markers for damp-heat accumulation syndrome with equal severity of dampness and heat. L-carnitine （AUC=0.77） may be a diagnostic biomarker for the heavier dampness syndrome type. Conclusion： There are differential metabolites and common metabolites among different subtypes of CHB with damp-heat accumulation syndrome. A deeper understanding of the metabolic commonalities and biases among different subtypes is of great significance for the fine differentiation of Chinese medicine and provides objective basis for the refinement of Chinese medicine classification.